Comments to FDA: Circumstances Under Which an Active Ingredient May be Simultaneously Marketed in Both a Prescription Drug Product and an OTC Drug Product

CHPA sees no need for the agency to initiate a rulemaking on this matter. Sufficient precedent already exists for an active drug ingredient to be simultaneously marketed in both prescription and OTC drug products based on narrow distinctions.